A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Hexarelin is a synthetic 6-amino-acid peptide and the most potent growth hormone releaser in its family (the GHRP class) — producing a stronger peak growth hormone response than GHRP-2, GHRP-6, or Ipamorelin in head-to-head comparisons. Like Ipamorelin, it works by activating the ghrelin receptor, but at a higher potency.
What genuinely sets Hexarelin apart, and it’s rare for a compound in this space, is that it has real published, peer-reviewed human clinical trial data behind one specific use: heart function. In a controlled human study, Hexarelin improved cardiac performance (left ventricular ejection and hemodynamics) in coronary artery disease patients undergoing bypass surgery. What makes this finding especially interesting is that the same benefit did NOT show up with GHRH or growth hormone itself given at doses producing similar GH elevation — meaning Hexarelin’s heart benefit works through a separate pathway entirely, not just through raising growth hormone.
Hexarelin directly activates receptors on heart muscle cells (cardiomyocytes) independent of its growth-hormone-releasing effect, and animal research on heart attack recovery backs this up — reduced damage size, reduced scarring, and better heart remodeling after a heart attack, again apparently separate from the GH pathway. It has even been used diagnostically in endocrinology as a growth-hormone stimulation test because its GH response is so reliable and potent.
The tradeoff is real, though: Hexarelin’s receptor desensitizes quickly, with studies showing roughly a 50% drop in GH response after 4 weeks of continuous daily use. That’s the main reason it’s typically cycled (2–4 weeks on, then an equal or longer break) rather than used continuously, and it’s also likely why, despite the promising cardiac data, it never advanced toward formal regulatory approval. It also tends to raise cortisol and prolactin more than gentler options like Ipamorelin, which is worth knowing if you’re combining peptides.
The growth hormone / IGF-1 pathway Hexarelin engages ultimately drives protein synthesis, which requires adequate dietary protein and amino acids as raw material, along with zinc and magnesium, which support several steps in GH signaling.
Hexarelin is not FDA-approved for any indication, and despite its published cardiac trial data, no company has pursued a formal regulatory approval pathway for it in any major jurisdiction. In the current US supply chain, it’s available only as a research compound. This page is for education only and is not an offer to provide Hexarelin outside an individualized clinical evaluation.
Yes. Growth hormone (HGH) tells the body to use fat as a fuel source. HGH rises during fasting so your body burns fat instead of sugar. HGH also increases the body’s production of IGF-1, which is quite anabolic and helps build muscle tissue.
Hexarelin and ipamorelin both act on the ghrelin receptor to release growth hormone, but hexarelin gives the biggest short-term pulse of the GHRPs, while ipamorelin gives a smaller, cleaner one. Hexarelin also raises cortisol, ACTH and prolactin, stimulates appetite more, binds the heart receptor CD36, and fades with daily use. In one 16-week study, the growth hormone response fell by about half and recovered after a break. Ipamorelin does not raise cortisol or prolactin at normal doses, the hunger is milder, and the effect holds up better. Hexarelin is a short-blast peptide; ipamorelin is the one used for ongoing dosing.
The research is early and not conclusive, but so far it looks protective for the heart. It helped restore ejection fraction (the amount of blood pumped out of the heart with each beat) and helped the heart repair faster.
The receptor it docks with gets fatigued, so the signal to produce HGH weakens with use. It comes back after a short break. Ipamorelin has the same problem, so we recommend running it for about 10 weeks and then taking about a 6-week break. You cannot switch between hexarelin and ipamorelin during the break, because they hit the same receptor.
Yes. Unlike ipamorelin, hexarelin raises cortisol, ACTH and prolactin along with growth hormone. Human studies of repeated daily dosing showed all three going up, closer to a stress-hormone challenge than a clean growth hormone pulse. The rise is dose-related, which is a main reason it isn’t used for ongoing dosing the way ipamorelin is.
I don’t think it’s a good fit for most people. In my opinion, the rise in cortisol, prolactin and ACTH is not worth the short-lived boost in HGH. Many compounds are on this site for information, not because people should be taking them.
Learn more about the pathway Hexarelin works within: Growth Hormone & IGF-1 and Ghrelin, the hormone that shares Hexarelin’s receptor. Compare with Sermorelin and Ipamorelin.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
